Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
September 02 2024 - 6:40PM
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation
company engineering high-fidelity vaccines to protect humankind
from the consequences of bacterial diseases, today announced it
will hold a webcast and conference call tomorrow, September 3,
2024, at 8:00 a.m. Eastern Time to present topline results from the
Phase 1/2 study evaluating the safety, tolerability and
immunogenicity of VAX-31, the Company’s 31-valent pneumococcal
conjugate vaccine (PCV) candidate designed to prevent invasive
pneumococcal disease (IPD), in healthy adults aged 50 and older.
To participate in the conference call, please dial
800-225-9448 (domestic) or 203-518-9708 (international) and refer
to conference ID PCVX0903. A live webcast of the conference call
will also be available on the investor relations page of
the Vaxcyte corporate website at www.vaxcyte.com. After
the live webcast, the event will remain archived on
the Vaxcyte website for 30 days.
About VaxcyteVaxcyte is a vaccine
innovation company engineering high-fidelity vaccines to protect
humankind from the consequences of bacterial diseases. The Company
is developing broad-spectrum conjugate and novel protein vaccines
to prevent or treat bacterial infectious diseases. Vaxcyte’s lead
candidate, VAX-24, is a Phase 3-ready 24-valent, broad-spectrum,
carrier-sparing PCV being developed for the prevention of IPD.
VAX-31, the Company’s next-generation 31-valent PCV, is the
broadest-spectrum PCV candidate in the clinic today. Both VAX-24
and VAX-31 are designed to improve upon the standard-of-care PCVs
for both children and adults by covering the serotypes that are
responsible for a significant portion of IPD in circulation and are
associated with high case-fatality rates, antibiotic resistance and
meningitis, while maintaining coverage of previously circulating
strains that are currently contained through continued vaccination
practice.
Vaxcyte is re-engineering the way highly complex
vaccines are made through modern synthetic techniques, including
advanced chemistry and the XpressCF™ cell-free protein synthesis
platform, exclusively licensed from Sutro Biopharma, Inc. Unlike
conventional cell-based approaches, the Company’s system for
producing difficult-to-make proteins and antigens is intended to
accelerate its ability to efficiently create and deliver
high-fidelity vaccines with enhanced immunological benefits.
Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine
candidate designed to prevent Group A Strep infections; VAX-PG, a
therapeutic vaccine candidate designed to slow or stop the
progression of periodontal disease; and VAX-GI, a vaccine candidate
designed to prevent Shigella. Vaxcyte is driven to eradicate or
treat invasive bacterial infections, which have serious and costly
health consequences when left unchecked. For more information,
visit www.vaxcyte.com.
Contacts:
Patrick Ryan, Executive Director, Corporate
CommunicationsVaxcyte, Inc.415-606-5135media@vaxcyte.com
Jennifer Zibuda, Senior Director, Investor
Relations Vaxcyte, Inc.860-729-8902investors@vaxcyte.com
Vaxcyte (NASDAQ:PCVX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vaxcyte (NASDAQ:PCVX)
Historical Stock Chart
From Sep 2023 to Sep 2024